In a Phase 1 clinical trial for zilebesiran, Desai et. al found that a single injection of this RNA interference therapy reduced high blood pressure for up to 24 weeks.

An RNAi therapy uses small pieces of non-coding RNA to block how certain genes are expressed. In 2018, Alnylam Pharmaceuticals’ Onpattro became the first FDA-approved RNAi drug.

As shown in STAT’s Obesity Drug Tracker, Regeneron and others are using RNA interference to target genetics, rather than hormones like GLP-1.

RNA interference (RNAi) is a natural mechanism for controlling gene expression. 1 It is also commonly referred to as post-transcriptional gene silencing (PTGS). 2 Common to plants, animals, fungi, and ...

More information: Matteo Iannacone et al, Targeting HBV with RNA interference: Paths to cure, Science Translational Medicine (2025). DOI: 10.1126/scitranslmed.adv3678 Provided by Saint Louis ...

RNA interference (RNAi) is a natural biological process that regulates gene expression by silencing specific genes. It involves small RNA molecules, such as small interfering RNAs (siRNAs) and miRNAs ...

RNA interference (RNAi) is a widely applied method, offering a fast and easy system to study gene functions. In this talk, we will take a look at the technology of endoribonuclease-prepared siRNAs ...

We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in ...

Fueling the Fires of RNA Interference World RNAi Market 2010Contract service = outsourced research/target validation projects Total = Projected worldwide RNAi revenues for 2010, in US dollars Source: ...